Ardea Biosciences, Inc.
Ardea Biosciences Announces Progress of Clinical Development Programs and Reports Third Quarter and Year-to-Date 2008 Financial Results
Published in Medical Letter on the CDC and FDA, December 7th, 2008
"We have continued to make significant progress since providing our second quarter 2008 update. In August, we initiated a Phase 1 study in normal healthy volunteers of RDEA594, our lead product candidate for the treatment of hyperuricemia and gout, and recently reported positive preliminary results from that trial, including a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- HIV/AIDS
Research on HIV/AIDS discussed by scientists at University of Massachusetts, Medical Department - Merck & Co., Inc.
GARDASIL, Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males in Phase III Study - Pharmacology
Research from Hamline University broadens understanding of pharmacology - Schizophrenia Therapy
Investigators at University Diego Portales release new data on schizophrenia therapy - Astigmatism
Studies by D.R. Sanders and co-authors describe new findings in astigmatism - Diabetes
Findings from C.M. Toscano and co-authors broaden understanding of diabetes - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
